0001491519-19-000001.txt : 20190125 0001491519-19-000001.hdr.sgml : 20190125 20190125144918 ACCESSION NUMBER: 0001491519-19-000001 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190123 FILED AS OF DATE: 20190125 DATE AS OF CHANGE: 20190125 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Davis Chaim CENTRAL INDEX KEY: 0001491519 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-28666 FILM NUMBER: 19542343 MAIL ADDRESS: STREET 1: 2601 PINE TREE DRIVE CITY: MIAMI BEACH STATE: FL ZIP: 33140 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMERICAN BIO MEDICA CORP CENTRAL INDEX KEY: 0000896747 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 141702188 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 122 SMITH ROAD CITY: KINDERHOOK STATE: NY ZIP: 12106 BUSINESS PHONE: 5187588158 MAIL ADDRESS: STREET 1: 122 SMITH ROAD CITY: KINDERHOOK STATE: NY ZIP: 12106 4 1 primary_doc.xml PRIMARY DOCUMENT X0306 4 2019-01-23 0 0000896747 AMERICAN BIO MEDICA CORP abmc 0001491519 Davis Chaim 80 BRAINARD ROAD WEST HARTFORD CT 06117 1 0 0 0 Common Shares 2019-01-23 4 A 0 38993 0.08 A 132536 D Common Shares 2019-01-23 2018-12-24 4 P 0 500000 0.1 A 2449915 I By Revach Fund, LP Non-Statutory Stock Option 0.18 2013-04-26 4 J 0 50000 0.18 A 2014-04-26 2023-04-26 Common Shares 50000 50000 D 38,993 shares of restricted stock were issued to Davis as compensation for his attendance at a meeting of the Company's Board of Directors held in January 2019. This stock issuance is in accordance with the director compensation structure approved by the Company's Board of Directors on March 22, 2018 (as indicated in the Company's Proxy Statement filed with the Commission on April 20, 2018). The volume weighted average price of the Company's common shares for the 10 days preceding the issuance was $0.0833 per share. These restricted shares of common stock were issued in connection with a private placement of up to 2,000,000 units of common stock as disclosed in a Current Report on Form 8-K filed with the Commission on December 24, 2018. Due to a technical delay, the actual issuance of the shares was not affected until January 25, 2019. The restricted common shares were issued in connection with a private placement completed on December 24, 2018. The Revach Fund, LP was one of the accredited investors who participated in the private placement. 500,000 units were purchased at $0.10 per share; resulting in a total purchase price of $50,000. Davis is a managing member of Revach Group, LLC which operates as the general partner for the Revach Fund,LP. Davis serves as the Chairman of the Board of the Company. The price per unit in the private placement was $0.10 per share. The common shares are in the name of Revach Fund, LP. The reporting person (Davis) is a managing member of Revach Group, LLC which operates as the general partner for the Revach Fund, LP. This non-statutory stock option was previously reported on a Form 3 filed by Davis on April 19, 2018.This stock option is being re-stated on this Form 4. It is not a new award. Chaim Davis 2019-01-25